title: Comparison of reducing effect on lung injury of dexamethasone and bosentan in acute lung injury: an experimental study.
abstract: BACKGROUND
  Different medical therapies are employed in acute lung injury (ALI) but there is still a debate about the efficacy of these drugs. Among these therapies steroids are clinically applied and bosentan is experimentally studied. The aim of this study was to evaluate the efficacy of these two drugs to treat inflammation in ALI by histopathological comparison.
  
  
  METHODS
  The five experimental groups (n = 5 per group) were: saline control (Group I); lipopolysaccharide (LPS) + saline (Group II); LPS + dexamethasone (Group III); LPS + 50 mg/kg bosentan (Group IV); and LPS + 100 mg/kg bosentan (Group V). Bosentan was administered orally one hour before and 12 hours after LPS treatment. Dexamethasone was administered intraperitoneally in three doses of 1 mg/kg; one dose was co-administered with LPS and the other two doses were given respectively 30 minutes before and after LPS treatment. Vasodilation-congestion, hemorrhage, polymorphonuclear leukocyte (PMN) infiltration, mononuclear leukocyte (MNL) infiltration, alveolar wall thickening, alveolar destruction/emphysematous appearance, and focal organization were the parameters used as criteria for evaluating inflammation and efficacy of treatment.
  
  
  RESULTS
  Compared to the LPS-only group (Group II), dexamethasone treatment (Group III) resulted in significant improvements in vasodilation-congestion, hemorrhage, PMN and MNL infiltration, alveolar wall thickening and emphysematous areas. Treatment with 50 mg/kg dose of bosentan (Group IV) also resulted in significant improvements in hemorrhage, PMN and MNL infiltration, alveolar wall thickening and alveolar destruction. Reducing lung injury and reparative effects of 100 mg/kg bosentan were significant in all parameters.
  
  
  CONCLUSIONS
  Bosentan is as effective as dexamethasone for treating lung injury in ALI. Bosentan at 100 mg/kg can be recommended as a first treatment choice based on its significant reducing lung injury and reparative effects.
authors.affiliation: Department of Pulmonary Diseases, Ataturk University School of Medicine, Erzurum, Turkey. dromeraraz@gmail.com.
authors.forename: Omer
authors.initials: O
authors.lastname: Araz
authors.forename: Elif
authors.initials: E
authors.lastname: Demirci
authors.forename: Elif
authors.initials: E
authors.lastname: Yilmazel Ucar
authors.forename: Muhammet
authors.initials: M
authors.lastname: Calik
authors.forename: Didem
authors.initials: D
authors.lastname: Pulur
authors.forename: Adem
authors.initials: A
authors.lastname: Karaman
authors.forename: Muhammed
authors.initials: M
authors.lastname: Yayla
authors.forename: Eren
authors.initials: E
authors.lastname: Altun
authors.forename: Zekai
authors.initials: Z
authors.lastname: Halici
authors.forename: Metin
authors.initials: M
authors.lastname: Akgun